Study finds how pembrolizumab helps in cervical cancer treatment
ANI
Washington, January 26
Chemotherapy and pembrolizumab have been approved for the treatment of women with metastatic, recurring, or…
Browsing Tag
Pembrolizumab
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of…
The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial ONC-392 is the first known…
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in…
BELTSVILLE, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class…
Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer
PARIS -- Combining a PD-1 inhibitor with standard chemoradiotherapy (CRT) failed to significantly improve survival outcomes in…
Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose…
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more checkpoint-inhibitor regimen, across a range of…
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of…
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies…
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate…
CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small…
Anti-LAG-3, Pembrolizumab Doublet Continues to Impress in Metastatic NSCLC
At the recent American Society of Clinical Oncology (ASCO) annual meeting, updated results of a phase II trial…
ASCO: Ramucirumab Plus Pembrolizumab Promising in NSCLC
Physician’s Briefing Staff
THURSDAY, June 9, 2022 (HealthDay News) -- Early research shows that overall survival is longer with ramucirumab and…
Athenex 宣佈與 Merck 開展臨床合作以評估 Oraxol 加 KEYTRUDA® (pembrolizumab) 在非小細胞肺癌 (NSCLC) 患者中的療效
紐約州水牛城, May 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX) 是一家致力於研究、開發及將治療癌症及相關疾病新療法商業化的全球生物製藥公司。今天宣佈與 Merck（在美國和加拿大以外稱為 MSD）達成臨床試驗合作和供應協議。該協議適用於在第 1 期臨床試驗擴展階段評估在某些非小細胞肺癌患者聯合使用…